Literature DB >> 2168977

Recombinant feline herpesviruses expressing feline leukemia virus envelope and gag proteins.

G E Cole1, S Stacy-Phipps, J H Nunberg.   

Abstract

We constructed recombinant feline herpesviruses (FHVs) expressing the envelope (env) and gag genes of feline leukemia virus (FeLV). Expression cassettes, utilizing the human cytomegalovirus immediate-early promoter, were inserted within the thymidine kinase gene of FHV. The FeLV env glycoprotein expressed by recombinant FHV was processed and transported to the cell surface much as in FeLV infection, with the exception that proteolytic processing to yield the mature gp70 and p15E proteins was less efficient in the context of herpesvirus infection. Glycosylation of the env protein was not affected; modification continued in the absence of efficient proteolytic processing to generate terminally glycosylated gp85 and gp70 proteins. A recombinant FHV containing the FeLV gag and protease genes expressed both gag and gag-protease precursor proteins. Functional protease was produced which mediated the proteolytic maturation of the FeLV gag proteins as in authentic FeLV infection. Use of these recombinant FHVs as live-virus vaccines may provide insight as to the role of specific retroviral proteins in protective immunity. The current use of conventional attenuated FHV vaccines speaks to the wider potential of recombinant FHVs for vaccination in cats.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168977      PMCID: PMC247984          DOI: 10.1128/JVI.64.10.4930-4938.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  A vaccine strain of pseudorabies virus with deletions in the thymidine kinase and glycoprotein X genes.

Authors:  C C Marchioli; R J Yancey; R C Wardley; D R Thomsen; L E Post
Journal:  Am J Vet Res       Date:  1987-11       Impact factor: 1.156

2.  Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses.

Authors:  P R Donahue; E A Hoover; G A Beltz; N Riedel; V M Hirsch; J Overbaugh; J I Mullins
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Processing of gag precursor polyprotein of human T-cell leukemia virus type I by virus-encoded protease.

Authors:  S H Nam; M Kidokoro; H Shida; M Hatanaka
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

4.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

5.  Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.

Authors:  B Dietzschold; H H Wang; C E Rupprecht; E Celis; M Tollis; H Ertl; E Heber-Katz; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus.

Authors:  R L Dewar; V Natarajan; M B Vasudevachari; N P Salzman
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

7.  Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.

Authors:  J M McCune; L B Rabin; M B Feinberg; M Lieberman; J C Kosek; G R Reyes; I L Weissman
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

8.  A herpesvirus vector for expression of glycosylated membrane antigens: fusion proteins of pseudorabies virus gIII and human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  M E Whealy; K Baumeister; A K Robbins; L W Enquist
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

9.  A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection.

Authors:  S Jonjić; M del Val; G M Keil; M J Reddehase; U H Koszinowski
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

Review 10.  Feline leukemia/sarcoma viruses and immunodeficiency.

Authors:  J Rojko; M Essex; Z Trainin
Journal:  Adv Vet Sci Comp Med       Date:  1988
View more
  6 in total

1.  Identification and DNA sequence analysis of the Marek's disease virus serotype 2 genes homologous to the thymidine kinase and UL24 genes of herpes simplex virus type 1.

Authors:  Y Shimojima; H K Jang; M Ono; K Maeda; Y Tohya; T Mikami
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

2.  Identification and nucleotide sequence of the thymidine kinase gene of canine herpesvirus.

Authors:  X Xuan; K Maeda; Y Tohya; T Mikami; H Otsuka
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

3.  Biosynthesis of glycoproteins E and I of feline herpesvirus: gE-gI interaction is required for intracellular transport.

Authors:  J D Mijnes; L M van der Horst; E van Anken; M C Horzinek; P J Rottier; R J de Groot
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

4.  Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.

Authors:  J H Nunberg; W A Schleif; E J Boots; J A O'Brien; J C Quintero; J M Hoffman; E A Emini; M E Goldman
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Vaccine efficacy of recombinant feline herpesvirus type 1 expressing immunogenic proteins of feline calicivirus in cats.

Authors:  N Yokoyama; K Maeda; K Fujita; S Ishiguro; T Sagawa; M Mochizuki; Y Tohya; T Mikami
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Pathogenicity and vaccine efficacy of a thymidine kinase-deficient mutant of feline herpesvirus type 1 in cats.

Authors:  N Yokoyama; K Maeda; Y Tohya; Y Kawaguchi; Y S Shin; M Ono; S Ishiguro; Y Fujikawa; T Mikami
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.